Maximum Dose of Paxil (Paroxetine)
The maximum recommended dose of paroxetine (Paxil) for adults is 50 mg/day for major depressive disorder, 60 mg/day for panic disorder and obsessive-compulsive disorder, and 75 mg/day for panic disorder with Paxil CR formulation 1.
Dosing by Indication
Major Depressive Disorder
- Starting dose: 20 mg/day (immediate-release) or 25 mg/day (Paxil CR)
- Maximum dose: 50 mg/day (immediate-release) or 62.5 mg/day (Paxil CR)
- Increase in 10 mg increments (immediate-release) or 12.5 mg increments (CR) at weekly intervals 1
- Most patients respond adequately to 20 mg/day; higher doses should only be used if no response after 1-3 weeks 2
Panic Disorder
- Starting dose: 10 mg/day (immediate-release) or 12.5 mg/day (Paxil CR)
- Maximum dose: 60 mg/day (immediate-release) or 75 mg/day (Paxil CR)
- Increase in 10 mg increments at weekly intervals 1
Obsessive-Compulsive Disorder
- Effective doses: 40-60 mg/day
- Maximum dose: 60 mg/day
- The 20 mg/day dose is NOT effective for OCD; doses of 40 mg/day and 60 mg/day show significant efficacy 3
Social Anxiety Disorder
- Starting dose: 20 mg/day (immediate-release) or 12.5 mg/day (Paxil CR)
- Maximum dose: 50 mg/day (immediate-release) or 37.5 mg/day (Paxil CR)
- Effective range is typically 20-50 mg/day 4
Generalized Anxiety Disorder
- Maximum dose: 50 mg/day
Premenstrual Dysphoric Disorder
- Maximum dose: 25 mg/day (Paxil CR only)
Special Populations
Elderly Patients (≥65 years)
- Starting dose: 10 mg/day (immediate-release) or 12.5 mg/day (Paxil CR)
- Maximum dose: 40 mg/day (immediate-release) or 50 mg/day (Paxil CR)
- Elderly patients have significantly higher plasma concentrations and prolonged half-life, requiring dose reduction 5, 1
Patients with Hepatic or Severe Renal Impairment
- Starting dose: 10 mg/day (immediate-release) or 12.5 mg/day (Paxil CR)
- Maximum dose: 40 mg/day (immediate-release) or 50 mg/day (Paxil CR)
- These patients have increased bioavailability and reduced clearance 1
Critical Safety Considerations
CYP2D6 Poor Metabolizers
Paroxetine is metabolized primarily by CYP2D6, which exhibits genetic polymorphism. CYP2D6 poor metabolizers have 3.8-fold higher paroxetine concentrations than extensive metabolizers and may require only 25% of the standard starting dose 6. CYP2D6 intermediate metabolizers have 2.2-fold higher concentrations and may require 50% of the standard dose 6.
Drug Interactions
Paroxetine has the highest inhibitory constant for CYP2D6 of all antidepressants (Ki = 0.065-4.65 micromoles), making it prone to significant drug-drug interactions 7. It also inhibits CYP3A4 8. Avoid combining with MAOIs, other serotonergic drugs, and drugs metabolized by CYP2D6 8.
Discontinuation Syndrome
Paroxetine has the highest risk of discontinuation syndrome among SSRIs due to its short half-life and potent serotonin transporter affinity 8. Always taper slowly over 10-14 days when discontinuing 5.
Pregnancy and Breastfeeding
Paroxetine is not preferred for new episodes during pregnancy due to associations with birth defects and gestational hypertension 9. However, switching medications during ongoing treatment is discouraged 9. If used, neonates require observation for withdrawal symptoms 1.
Suicidality Risk
Paroxetine carries a black box warning for treatment-emergent suicidality, particularly in adolescents and young adults aged 18-24 years, with the highest risk in the first month of treatment 10, 11. Close monitoring is essential, especially during dose changes 12.
Common Pitfalls
- Do not use 20 mg/day for OCD—this dose is ineffective; start at 40 mg/day 3
- Do not exceed 40 mg/day in elderly patients or those with hepatic/renal impairment 1
- Do not combine with tamoxifen—paroxetine inhibits conversion to active endoxifen, increasing breast cancer mortality risk 11, 7
- Do not abruptly discontinue—paroxetine has the highest discontinuation syndrome risk among SSRIs 8